Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
SOPHiA GENETICS Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
SOPHiA GENETICS has a total shareholder equity of $121.4M and total debt of $13.3M, which brings its debt-to-equity ratio to 11%. Its total assets and total liabilities are $181.1M and $59.7M respectively.
Anahtar bilgiler
11.0%
Borç/özkaynak oranı
US$13.34m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$105.40m |
| Eşitlik | US$121.44m |
| Toplam yükümlülükler | US$59.65m |
| Toplam varlıklar | US$181.10m |
Son finansal sağlık güncellemeleri
Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Dec 27
Is SOPHiA GENETICS (NASDAQ:SOPH) In A Good Position To Invest In Growth?
Aug 08Here's Why We're Watching SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Dec 15We're Hopeful That SOPHiA GENETICS (NASDAQ:SOPH) Will Use Its Cash Wisely
Jul 01We Think SOPHiA GENETICS (NASDAQ:SOPH) Can Afford To Drive Business Growth
Mar 10Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Nov 24Recent updates
SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported, And Analysts Assigned A US$6.00 Price Target
Aug 09Investors Still Waiting For A Pull Back In SOPHiA GENETICS SA (NASDAQ:SOPH)
Aug 08SOPHiA GENETICS SA (NASDAQ:SOPH) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Mar 09Sophia Genetics: Breakthrough Potential In A Cautious Healthcare Sector
Feb 12Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Dec 27Why Investors Shouldn't Be Surprised By SOPHiA GENETICS SA's (NASDAQ:SOPH) 35% Share Price Surge
Nov 09Is SOPHiA GENETICS (NASDAQ:SOPH) In A Good Position To Invest In Growth?
Aug 08Here's Why We're Watching SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Dec 15SOPHiA GENETICS partnering with Boundless Bio on oncogene cancer therapies
Sep 21SOPHiA Genetics GAAP EPS of -$0.39 in-line, revenue of $11.7M misses by $0.25M
Aug 09We're Hopeful That SOPHiA GENETICS (NASDAQ:SOPH) Will Use Its Cash Wisely
Jul 01SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 18We Think SOPHiA GENETICS (NASDAQ:SOPH) Can Afford To Drive Business Growth
Mar 10Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Nov 24Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: SOPH's short term assets ($125.8M) exceed its short term liabilities ($28.6M).
Uzun Vadeli Yükümlülükler: SOPH's short term assets ($125.8M) exceed its long term liabilities ($31.0M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: SOPH has more cash than its total debt.
Borcun Azaltılması: Insufficient data to determine if SOPH's debt to equity ratio has reduced over the past 5 years.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: SOPH has sufficient cash runway for more than a year based on its current free cash flow.
Tahmini Nakit Akışı: Insufficient data to determine if SOPH has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.